onset of hypoxaemic respiratory failure, which is accompanied by bilateral infiltrates of chest, and occurs due to non-cardiogenic cause.
1,2 Despite vigorous researches on pharmacological treatment and ventilator strategy in recent decades, ARDS with ORIGINAL ARTICLE the 22 patients who had identifiable infective causes, those suffering from viral infection had lower intensive care unit and hospital mortality than those who had bacterial infection (8.3% vs 20.0%). All the H1N1 patients survived. Complications related to extracorporeal membrane oxygenation included severe bleeding (n=2; 6.5%) and mechanical complications of the circuits (n=3; 9.7%).
Conclusions:
Venovenous extracorporeal membrane oxygenation is an effective adjunctive therapy and can be used as a life-saving procedure for carefully selected patients with severe acute respiratory distress syndrome when the limits of standard therapy have been reached. 4 With the evolution of technology, the procedure has become simpler, safer, and more reliable. Since 2010, the Queen Elizabeth Hospital (QEH) in Hong Kong has started providing venovenous (v-v) ECMO to selected patients with severe respiratory failure due to severe ARDS and profound hypoxaemia.
Methods
This was a retrospective observational study performed in a 19-bed ICU of a tertiary hospital in Hong Kong. Eligible patients needed to have potentially reversible causes for respiratory failure, refractory respiratory failure despite maximum conventional ventilator support, and Murray score of 3.0 or higher (Murray score 4 is calculated by: PaO 2 / FiO 2 ratio, positive end-expiratory pressure [PEEP], lung compliance, chest radiographic appearance). Patients with acute-status asthmaticus and refractory respiratory failure were also selected as candidates for ECMO despite having Murray score of lower than 3.0. Patients were excluded for ECMO therapy if they had intracranial bleeding; severe, irreversible brain damage; or were older than 70 years.
Extracorporeal membrane oxygenation retrieval
The QEH ECMO team supports eligible patients from other ICUs that do not have ECMO service. The QEH ECMO retrieval team puts eligible patients in the referring hospitals on ECMO circuit, and then escorts them to QEH. The team consists of two intensivists and two intensive care nurses.
Technique of extracorporeal membrane oxygenation setup
Access catheters (Maquet HLS, Germany; BIOLINE coating) were inserted in either the right or left femoral vein, and return catheters were inserted in the right internal jugular vein. All cannulation procedures were performed at the bedside, by ICU specialists, with Seldinger technique and ultrasound guidance. The size of the cannulas was chosen according to the body weight of patients. The default size was 19 Fr for return catheter and 23 Fr for access catheter. The jugular-femoral approach for return (19 Fr) and access (23 Fr) catheter cannulation was adopted for all patients. The catheters were connected to the ECMO machine (either Rotaflow: BE-PLS 12050-Quadrox PLS [Jostra], or Cardiohelp: HLS module advanced 7.0).
Extracorporeal membrane oxygenation care
As per our ICU ECMO protocol, ECMO nurses and ECMO specialists have to provide special regular monitoring of coagulation status, circuit conditions, perfusion status, and neurological status. Accordingly, unfractionated heparin infusion is the default and only anticoagulant used. Anticoagulation is monitored at the bedside with a target-activated clotting time of 180-220 seconds. Activated clotting time is measured every 4 hours. We maintain a platelet count of 100 x 10 9 /L, international normalised ratio of <1.5, and haemoglobin level of >120 g/L. The ECMO nurses need to check the following every 4 hours: presence of clot in the oxygenator membrane, any colour difference between the access and return catheters, and oxygenator membrane pressure gradient. The post-oxygenator partial pressure of oxygen and freehaemoglobin level are checked daily.
Other routine care
We use benzodiazepine and narcotics for sedation.
Pupil size, sedation score, and conscious status are assessed every 4 hours. Propofol is not recommended due to the potential interaction with oxygenator membrane. Enteral nutrition is used when possible, and as early as possible, according to our ICU feeding protocol. Fluid balance is maintained with diuretics and continuous v-v haemofiltration, as clinically indicated.
Ventilation strategy
Once the ECMO support is started, we change the ventilator setting so as to allow 'lung rest' (ie FiO 2 0.4, PEEP 10 cm H 2 O, tidal volume 4 mL/kg, rate 10 cycles/min) with an inspiratory/expiratory ratio of 1:1.3.
Renal replacement therapy
Continuous v-v haemofiltration is used for patients with acute kidney injury, excessive fluid gain, and metabolic acidosis. The venous and arterial lines are connected at post-pump to minimise the risk of air embolism.
Decannulation
Heparin infusion is stopped 30 minutes before decannulation. Decannulation is performed at the bedside with two-team approach. Both jugular and femoral catheters are removed simultaneously. Direct pressure is then applied to the sites for at least 15 minutes.
Statistical analysis
Normally distributed data were expressed as mean ± standard deviation (SD (Table 1 ). The mean duration of mechanical ventilation before starting ECMO treatment was 1.6 ± 2.7 days.
Male gender and younger age were associated with better survival rate, although they did not attain statistical significance. Survivors and non-survivors had similar Murray scores. Survivors had a higher pre-ECMO PaO 2 /FiO 2 ratio, lower APACHE (Acute Physiology And Chronic Health Evaluation) II and APACHE IV scores, and shorter time for symptoms to ICU admission versus the non-survivors, but none of the differences was statistically significant (Table  1) . Of the 31 patients who presented with respiratory failure, 28 (90.3%) were diagnosed to have pneumonia, one had severe smoke inhalation injury, and two had status asthmaticus; 22 of the 28 pneumonia patients had identifiable laboratory causes (Table 2) . Patients suffering from viral infection as primary cause of respiratory failure (1 dead/11 alive) had better ICU survival than those suffering from bacterial infection (2 dead/8 alive); however, the difference was not statistically significant (92% vs 80%, P=0.57, Fisher's exact test; Table 2 ). Overall, nine (29.0%) patients were diagnosed to have H1N1 infection, either by polymerase chain reaction or serology or both. Patients with H1N1 as the cause of respiratory failure had excellent survival outcome (100%; Table  3 ).
The median (IQR) duration of ECMO therapy was 5.0 (2.8-8.6) days. The median length of ICU stay was 18.0 (11.6-25.8) days, and median length of hospital stay was 23.5 (15.3-40.9) days. A total of 25 (80.6%) patients survived ICU discharge and 24 (77.4%) patients survived hospital discharge and had 28-day survival (Table 4) . 
Discussion
The first successful ECMO treatment case was reported in 1972. 5 However, two randomised controlled trials 6, 7 that were published several years after this reported case failed to show any significant advantage with ECMO. The use of ECMO in adult patients remained limited until publication of the CESAR trial in 2009, 3 which showed significant advantages with ECMO in terms of survival for patients with severe respiratory failure and ARDS after H1N1 pandemic.
Our patients, who were managed with v-v ECMO for severe respiratory failure, had ICU mortality and hospital mortality of 19.4% and 22.6%, respectively. Most of them (n=29; 93.6%) had severe ARDS that failed conventional treatment. Our results (7 dead/24 alive) compared favourably with the ECLS (Extracorporeal Life Support) Registry Report, 8 in which the hospital mortality was reported to be 44% (2283 dead/2905 alive; P=0.018 by Fisher's exact test). Mortality of ARDS, before 1990s, was higher than 50%. 9, 10 Mechanical ventilator is the cornerstone of treatment for ARDS. Although it can support lung ventilation, inappropriate use can lead to lung damage including excessive transpulmonary pressure (barotrauma), excessive lung volume inside alveoli (volutrauma), and shearing stress during repetitive opening and closing of alveoli (atelectrauma). 11 Moreover, the damage caused by mechanical ventilation is not limited to the lungs. Lung trauma can trigger systemic inflammatory response (biotrauma) that involves other distal organs leading to multiorgan damage. To date, the only strategy that can improve survival is lung protective strategy (≤6 mL/kg of predicted body weight; plateau pressure ≤30 cm H 2 O). 12, 13 With the use of lung protective strategy and ECMO treatment, recent publications reported a mortality of approximately 20% to 40%. 3, 14 Lung protective strategy was the most evidence-based approach in ARDS management. Extracorporeal membrane oxygenation use in ARDS patients can ensure the effective application of low tidal volume and plateau pressure strategy.
In our report, the mean tidal volume after ECMO therapy was 288.0 ± 76.8 mL, which was within the higher limit of the expected tidal volume (390 mL) according to the lung protective strategy ( Table 1 ). The ICU mortality and hospital mortality rates in our cases were 19.4% and 22.6%, respectively. These figures are favourable when compared with patients who receive only lung protective strategy. 13 In fact, ICU doctors often face challenges to comply with the lung protective strategy in real situation. The presence of stiff lung and hypercarbia in severe ARDS patients may make it difficult for ICU doctors to set low tidal volume and transpulmonary pressure. The use of ECMO, however, can overcome these challenges. Extracorporeal membrane oxygenation can allow both CO 2 removal and oxygenation with an independent circuit that by-passes the sick lungs. This permits complete lung rest with the lung protective strategy.
H1N1 infection is widely reported to have better survival rate and shorter duration of ECMO support, mechanical ventilator days, and length of ICU stay. According to the ELSO (Extracorporeal Life Support Organization) registry (as dated to 13 April 2011), the H1N1 survival rate was 76.8% (66 dead/218 alive) in patients older than 20 years. 15 In our study, all nine H1N1 swine flu patients survived (Table 2 ). H1N1 patients in Hong Kong had more favourable outcomes compared with those in Australia and Canada (Table 3) . 14, 16, 17 These outcomes included shorter ECMO duration, shorter ventilator days, and shorter ICU and hospital length of stay. Future study shall explore other factors that affect outcomes including duration of interhospital transportation, manpower availability, and use of pharmacological treatment. In our centre, Abbreviations: ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; LOS = length of stay * Mann-Whitney U test for comparison of medians In our study, vascular injury was the single complication that was related to the procedure. We encountered one oxygenator-related thrombosis and one suspected oxygenator failure. In one case, we postulated that the cause of thrombosis was hypercoagulopathy related to mycoplasma infection. Another case had contra-indication to heparin due to active bleeding. One patient was diagnosed with intracerebral bleeding after initiation of ECMO therapy. The bleeding was probably related to the patient's own brain pathology. The patient was diagnosed with haematological lymphoproliferative disease that probably infiltrated the brain and caused death, as suggested by the postmortem examination.
Limitations
Our report had several limitations. As ECMO therapy is relatively new in our centre, we have a limited number of cases. This study was a retrospective review of a single-centre experience. All patients who received ECMO therapy were carefully selected, and we did not have a control group to demonstrate the superiority of ECMO therapy. We only considered mortality as our main outcome and did not followup the long-term morbidity of the survivors. Future study with ECMO shall consider outcomes that cover physical, functional, and neuropsychological aspects.
Conclusions
Venovenous ECMO is an effective adjunctive therapy, useful as a life-saving procedure for carefully selected severe ARDS patients when the limits of standard therapy have been reached.
